New World Advisors LLC Raises Holdings in Zoetis Inc. (NYSE:ZTS)

New World Advisors LLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 22.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,384 shares of the company’s stock after buying an additional 631 shares during the quarter. Zoetis makes up approximately 0.1% of New World Advisors LLC’s investment portfolio, making the stock its 29th biggest holding. New World Advisors LLC’s holdings in Zoetis were worth $551,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Pensionfund Sabic increased its holdings in Zoetis by 55.6% during the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after buying an additional 4,000 shares during the period. Callahan Advisors LLC boosted its stake in Zoetis by 90.4% in the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after acquiring an additional 6,221 shares in the last quarter. PFW Advisors LLC acquired a new stake in Zoetis in the fourth quarter valued at approximately $1,764,000. CIBC Asset Management Inc boosted its stake in Zoetis by 24.1% in the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after acquiring an additional 46,050 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Zoetis by 10.6% in the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after acquiring an additional 279,092 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is currently owned by insiders.

Zoetis Trading Up 1.9 %

NYSE ZTS opened at $160.39 on Monday. The company has a market capitalization of $71.82 billion, a PE ratio of 29.32, a P/E/G ratio of 2.78 and a beta of 0.90. The company has a fifty day moving average of $166.51 and a 200 day moving average of $177.94. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.25%. Zoetis’s dividend payout ratio is presently 36.56%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ZTS shares. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Barclays raised their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Morgan Stanley lowered their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Stifel Nicolaus lowered their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Piper Sandler lowered their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average target price of $215.40.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.